A Phase I/II Institutional Study of Abraxane in Recurrent and Refractory Lymphoma

Trial Profile

A Phase I/II Institutional Study of Abraxane in Recurrent and Refractory Lymphoma

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 08 Dec 2016

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications B cell lymphoma; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 30 Jun 2016 Status changed from active, no longer recruiting to discontinued as the drug did not show activity, completed accrual to phase I but halted before initiation of phase II.
    • 10 Feb 2016 Planned End Date changed from 1 Jun 2015 to 1 Jun 2016, according to ClinicalTrials.gov record.
    • 10 Feb 2016 Planned primary completion date changed from 1 Jun 2015 to 1 Jun 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top